Chromocell Therapeutics Corp

PTHS

Explore Our Financial Data > Companies > Chromocell Therapeutics Corp

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	PTHS
CIK	0001919246
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	685 US HIGHWAY ONE, NORTH BRUNSWICK, NJ, 08902
Website	chromocell.com
Phone	9176446313
CEO	Francis Knuettel II
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-7.36 million
Net Income	$-7.36 million
Net Income to Common	$-7.36 million
EPS	N/A

View All

Balance Sheet

Cash	$131,317.00
Assets	$911,179.00
Liabilities	$5.11 million
Common Equity	$-4.20 million
Liabilities & Equity	$911,179.00

View All

Cash Flow Statement

Net Income	$-7.36 million
Cash From Operating Activities	$-4.43 million
Cash From Investing Activities	N/A
Cash From Financing Activities	$793,804.00
Change in Cash	$-3.64 million

View All

Calculations

NOPAT	$-5.23 million
EBITDA	$-7.29 million
Price to Earnings	N/A
Price to Book	N/A
ROE	480.19%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical co

Article Link

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the compl

Article Link

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company’s Common Stock and help the Company satisfy the initial listing requi

Article Link

MAIA Biotechnology, Roche sign supply agreement for cancer therapies

MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab. Published first on TheFly – the ultimate s

Article Link

Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz

The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S. initial jobless claims were unchanged at 248,000 in the week ended June 7, above expectations and holding at an eight-month high. Geopolitical concerns have also resurfaced; escalating tensions in the Middle East led to a sharp rise in oil prices and triggered safe-haven flows, which weighed on equities and the U.S. dollar. Meanwhile, U.S.-China trade progress continues

Article Link